P.U.L.S. further strengthens its project management team.
- Details
- Published on Monday, 22 September 2008 23:21
Stanko Skrtic, Chief Scientific Officer, and Maria Forss, Head of
business development, joined the PULS team of life sciences project
management and drug development experts in mid August. Stanko Skrtic M.D., Ph.D., M.B.A., Associate Professor in Clinical
Pharmacology, has been a PULS partner for a number of years and also a
founding innovator in several life sciences projects. Apart from his
role as Chief Scientific Officer in PULS, he will focus on DuoCort
Pharma, one of the PULS project companies that is currently in late
clinical development and preparing to submit a regulatory file during
2009.
Skrtic has most recently worked at Astra Zeneca and has a background in
research in experimental medicine and pharmacology at Sahlgrenska
University Hospital. He is the founder and director of several
biomedical start-ups. He will contribute with his broad experience in
pharmaceutical development encompassing preclinical and clinical
development within both SMEs and large pharmaceutical companies. Skrtic
also has experience of regulatory authority work.
Maria Forss, M Sc BA, comes most recently from the global marketing
organisation at AstraZeneca where she held the position of Brand Insight
Director. For the last 13 years Forss has worked in both local and
global marketing positions at AstraZeneca and brings a wealth of
experience of early drug development from a strategic marketing
perspective. She has successfully led cross functional projects over the
whole product life cycle and will broaden the competence base in PULS
to secure quality in both new and existing projects. Forss is also the
author of a book about quality work, "Att mäta kvalitet".
In addition to her role as Head of business development, Maria Forss
will also lead DuoCort Pharma in the lead-up to its coming market launch
and partnering process.
"We are delighted to be able to strengthen the scientific and business
development sides of PULS. This marks another step in our ambition to
become a leading actor in investments in life science. With more
personnel resources and broader expertise we can handle more project
evaluations, more investments and at the same time focus the exit
processes in existing project companies", says Pontus Ottosson, CEO of
PULS.
Download the entire press release here: